Drug intelligence / Profile preview

Omicron-adapted COVID-19 vaccine

Development stage: Unknown
Lead developer: Pfizer
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Omicron-adapted COVID-19 vaccine, developed by Pfizer and BioNTech, is an mRNA vaccine designed to protect against SARS-CoV-2, specifically targeting the Omicron variant. It works by delivering messenger RNA (mRNA) that instructs human cells to produce the spike protein of the Omicron variant, thereby stimulating an immune response to prevent or mitigate COVID-19. The U.S. government secured an agreement for 105 million doses of this vaccine, with deliveries planned for late 2022.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Omicron-adapted COVID-19 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omicron-adapted COVID-19 vaccine.

Explore the full profile